Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study

SIMPLE SUMMARY: This study compared the therapeutic efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib as first-line therapy for the treatment of unresectable hepatocellular carcinoma (HCC). A total of 232 patients from three academic hospitals in Korea were included. No signific...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Beom Kyung, Cheon, Jaekyung, Kim, Hyeyeong, Kang, Beodeul, Ha, Yeonjung, Kim, Do Young, Hwang, Seong Gyu, Chon, Young Eun, Chon, Hong Jae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996911/
https://www.ncbi.nlm.nih.gov/pubmed/35406518
http://dx.doi.org/10.3390/cancers14071747

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996911/
https://www.ncbi.nlm.nih.gov/pubmed/35406518
http://dx.doi.org/10.3390/cancers14071747

Ejemplares similares